Zimmer Biomet Holdings (ZIM) Price & Analysis
ZIM Stock Chart & Stats
- Day’s Range
- EUR 84.02 - EUR 85.68
- 52-Week Range
- EUR 67.36 - EUR 89.30
- Previous Close
- EUR 86.12
- Volume
- 245
- Average Volume (3M)
- 13
- Market Cap
- EUR 16.09B
- Enterprise Value
- EUR 23.68B
- Total Cash (Recent Filing)
- EUR 410.00M
- Total Debt (Recent Filing)
- EUR 7.48B
- Price to Earnings (P/E)
- 22.9
- Beta
- 0.44
- Next Earnings
- Nov 04, 2026
- EPS Estimate
- 1.68
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.01%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Improving operating and free cash flow indicates that Zimmer Biomet is converting sales and earnings into internally generated funding. This supports investment in products and commercial capabilities, strengthens financial resilience, and provides flexibility for capital returns or strategic uses.
Technology And Robotics Growth
Rapid growth in technology-enabled offerings gives Zimmer Biomet an expanding business beyond traditional implants. Strong ROSA adoption and continued robotics development can deepen surgeon relationships, support differentiated solutions, and increase exposure to higher-growth procedure-enabling categories.
Steady Revenue Growth And Raised Outlook
Consistent sales expansion across the business, together with raised full-year guidance, supports the durability of demand for Zimmer Biomet's orthopedic products. A stable growth profile improves planning visibility and helps fund ongoing innovation, market development, and commercial execution.
Bears Say
Margin Compression
Recent gross and operating margin declines show that investments in the U.S. commercial organization and higher manufacturing costs are weighing on profitability. If these costs persist, they could limit earnings conversion and reduce the financial benefit of otherwise steady revenue growth.
Pricing And Reimbursement Pressure
Pricing erosion directly threatens the economics of Zimmer Biomet's implant portfolio, while reimbursement changes can increase pressure on providers and purchasing decisions. Persistent pricing headwinds would make it harder to protect margins and translate procedure growth into comparable profit growth.
Knee And China Weakness
Weak knee performance affects a core reconstructive category and highlights uneven momentum across Zimmer Biomet's geographic markets. China and emerging-market softness can prolong international pressure, weaken mix, and require additional commercial effort before these areas contribute more strongly.
Zimmer Biomet Holdings News
Zimmer Biomet’s Vivacit-E Hip Liner Study Wrap-Up: What Investors Should Know
Zimmer Biomet Holdings ($ZBH) announced an update on their ongoing clinical study. The Vivacit-E Post-market Follow-up Study, officially titled “Post Market Clinical Follow-up Study of the Zimmer Vivacit-E Highly Crosslinked
ZIM FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
What is Zimmer Biomet Holdings’s market cap?
When is Zimmer Biomet Holdings’s upcoming earnings report date?
How were Zimmer Biomet Holdings’s earnings last quarter?
Is Zimmer Biomet Holdings overvalued?
Does Zimmer Biomet Holdings pay dividends?
What is Zimmer Biomet Holdings’s EPS estimate?
How many shares outstanding does Zimmer Biomet Holdings have?
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
What is the TipRanks Smart Score and how is it calculated?
Zimmer Biomet Holdings Stock Smart Score
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ivan Tornos
- Employees
- 17,000
- Website
- www.zimmerbiomet.com
- Address
- 345 East Main Street, Warsaw, IN, 46580, US
Zimmer Biomet Holdings (ZIM) Earnings & Revenues
ZIM Earnings Call
Earnings Call SentimentPositive
The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.
View all DE:ZIM earnings summariesZIM Net sales Breakdown
- 40.36% Knees
- 25.43% Hips
- 26.12% S.E.T
- 8.09% Technology & Data, Bone Cement and Surgical
ZIM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 10 | 0 | 2 |